All News
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis
Editor's note: This article was originally published April 22, 2025, and is being shared again as part of RheumNow's 'Best of 2025' series as we close out the year. Enjoy!
Read Article
Best of 2025: Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients
Despite advances in treatments reducing the need for major surgery, many rheumatic disease patients still require surgery while on DMARDs. A review of perioperative https://t.co/LHClCUvHrb
Dr. John Cush RheumNow ( View Tweet)
APP Pearls “It’s important to explain the difference between an overreactive immune system vs. a weakened immune system” - Miguel Rodriguez, ANP
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: ERS/EULAR guidelines for CTD-related interstitial lung disease
The ERS and EULAR have published clinical practice guidelines for the evaluation and management of CTD associated ILD in two simultaneous publications in the European Respiratory Journal and Annals of https://t.co/ceGCQjkmJV
Dr. John Cush RheumNow ( View Tweet)
"It's suppose to be hard, if it wasn't hard everyone would do it. Hard is what makes it great! - Tom Hanks in "League of Their Own"
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Targeting Obesity in Rheumatic Disease Patients
Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese. https://t.co/aPGuYFCWLo
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” https://t.co/hFejdS4sjk
Dr. John Cush RheumNow ( View Tweet)
APP Pearls “Ensure a patient understands the weekly dosing instructions for methotrexate” - Ben Smith, DMSc, PA-C
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Contraception in SLE
Pregnancy in SLE gets a lot of press in the rheumatology literature, and deservedly so, since pregnancy risks can be markedly increased. It was not that many years ago that women with SLE were counseled to avoid pregnancy. As recently as 2004, https://t.co/vBb0vyqod8
Dr. John Cush RheumNow ( View Tweet)
Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including:
nipocalimab
VAY736 (ianalumab)
HZN-1116
AMG 329
R-2487 https://t.co/sVbyPLi2Um https://t.co/2URpGUsMk9
Dr. John Cush RheumNow ( View Tweet)
Comprehensive review of the management of knee osteoarthritis - topicals, analgesics, narcotics, intraarticular, metabolic, nutraceuticals, TENS, acupuncture and biologics. https://t.co/3UjPQeZut9 https://t.co/z0dzENSbtX
Dr. John Cush RheumNow ( View Tweet)
Inflammatory vs. Noninflammatory Pain
https://t.co/ZZLMnT8IVO https://t.co/W0tVK75raN
Dr. John Cush RheumNow ( View Tweet)
SMART study - Single vs. Split Dose Methotrexate in RA
Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients.
https://t.co/JN5wPGNjao https://t.co/hI8dxWmZe8
Dr. John Cush RheumNow ( View Tweet)
APP Pearls “When I’m explaining treatment options, I say “hey you are the captain of this ship, I’m your co-captain. I help to guide you along this journey… (I can help you) avoid that Hurricane.” - April Woodrow, APRN, ANP-BC
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Glossary for Giant Cell Arteritis
Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving https://t.co/yfJXZx5r6G
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Glucocorticoids in SLE: how to start, how to follow, how to stop
70+ years after their debut, glucocorticoids remain a fast, powerful tool for SLE—but long-term toxicity comes at a high cost. Guidelines now favor GC “bridging therapy”: use briefly, taper fast. The https://t.co/RS0JQquv6j
Dr. John Cush RheumNow ( View Tweet)
APP Pearls “Steroids are not a long-term plan; AND One visit cannot fix everything” - Claudia Rivera-Salas, NP
Dr. John Cush RheumNow ( View Tweet)
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/gEqmkdJLDh https://t.co/Q0TKznTWdV
Dr. John Cush RheumNow ( View Tweet)
2025 update of EULAR recommendations on lupus nephritis
At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented updated EULAR recommendations on managing lupus nephritis (LN). The key change is that the historic standard of care (mycophenolate with https://t.co/78J1L80Zxe
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Distinguishing Septic and Gouty Arthritis
A single center, retrospective review of patients undergoing knee joint fluid aspirations for presumed crystalline arthritis (CA) showed that synovial WBC may provide a useful diagnostic marker for SA with an optimal https://t.co/G31CazbqmR
Dr. John Cush RheumNow ( View Tweet)
